Abstract Pharmacological evidence suggests the importance of noradrenergic and other monoaminergic neurotransmitters in the aetiology and treatment of attention deficit hyperactivity disorder (ADHD). Until recently, the genes of the noradrenergic pathway were not intensively investigated in ADHD compared to dopaminergic and serotonergic candidates. In this study, 91 SNP markers of 14 noradrenergic genes (an average density of one SNP per 4.5 kbp) were examined in ADHD samples from Ireland and Australia. Although suggestive evidence of association (nominal p≤0.05) with the genes SLC6A2, ADRA1A, ADRA1B and ADRA2B was observed, none remained significant after permutation adjustments. In contrast, haplotype analyses demonstrated a significant association between ADHD and a SLC6A2 haplotype comprising the markers rs36009, rs1800887, rs8049681, rs2242447 and rs9930182 (χ 2 09.39, p-corrected00.019, OR01.51). A rare ADRA1B haplotype made of six SNPs (rs2030373, rs6884105, rs756275, rs6892282, rs6888306 and rs13162302) was also associated (χ 2 07.79, p-corrected00.042 OR02.74) with the disorder. These findings provide evidence of a contribution of the noradrenaline system to the genetic aetiology of ADHD. The observed haplotype association signals may be driven by as yet unidentified functional risk variants in or around the associated regions. Functional genomic analysis is warranted to determine the biological mechanism of the observed association.
Introduction
Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder affecting 2-6 % of school-age children. The disorder is defined by persistent and pervasive inattention and/or hyperactive-impulsive behaviours that frequently impair social and academic functioning. Disruption in catecholamine neurotransmission has been implicated in several psychiatric conditions including ADHD. The hypothesis of catecholamine dysfunction in ADHD is derived from the neuropharmacology of stimulant medication used to treat ADHD (Amara and Kuhar 1993) , the behaviour and biochemistry of animal models (Giros et al. 1996; Gainetdinov et al. 1999; Russell 2000) , neuroimaging studies (Faraone and Biederman 2002; Swanson et al. 2007 ) and from recent molecular genetic studies (Albayrak et al. 2008) . Noradrenergic pathway genes have been less extensively examined in ADHD compared to dopaminergic and serotonergic pathway genes.
Noradrenergic projections are dense in the frontal cortex and cingulate gyrus. These regions form the neural substrate of an anterior attentional system that is responsible for maintaining alertness and exercising attentional control (Aston-Jones et al. 1999) . Animals and humans with lesions in the prefrontal cortex (PFC) show poor attention regulation, disorganised and impulsive behaviour and hyperactivity. Noradrenaline (NA), which is secreted in the locus coeruleus and released into the PFC, strengthens the working memory, behavioural inhibition and attentional functions of the PFC (Caballero and Nahata 2003) . Low concentrations of NA in the right dorsal and orbital sections of the PFC have been associated with many ADHD symptoms such as poor concentration, increased motor activity and lack of self control (Caballero and Nahata 2003) .
In human participants, treatment with clonidine (which stimulates the alpha2A post-synaptic adrenergic receptors) at low dosage was shown to result in increased attention lapses that were ameliorated using specific alpha2A antagonists (Smith and Nutt 1996) . In addition, locomotor hyperactivity induced by d-amphetamine, cocaine or morphine in mice lacking the alpha1b adrenergic receptor is dramatically decreased when compared with wild-type littermates. Moreover, behavioural sensitizations induced by these psychostimulants were significantly decreased in alpha1b knock-out mice compared to wild-type mice (Drouin et al. 2002) . Drugs that modulate NA transmission are also reported to be effective in the treatment of ADHD. NA inhibitors such as desipramine, nortriptyline and atomoxetine are used in the treatment of ADHD (Popper 2000; Davids et al. 2002) . Biederman et al. (2002) demonstrated that atomoxetine was superior to placebo in the treatment of individuals with ADHD. The mode of action of atomoxetine is to block the reuptake of NA and consequently increase the release of the monoamines into the extracellular space.
Isolated associations between ADHD and DNA variants of noradrenergic pathway genes have been reported. Association with DNA variants of the gene encoding dopamine beta hydroxylase (DBH) (Daly et al. 1999) and with the adrenergic receptors ADRA2A and ADRA2C (Comings et al. 1999 ) has been reported. Comings and colleagues (1999) reported a significant correlation between scores for ADHD, a history of learning disabilities and poor gradeschool academic performance that was greatest for the additive effect of all three genes. Combined, they estimated that these genes accounted for 3.5 % of the variance of the ADHD score (p00.0005). Early studies also reported association with catechol-o-methyltransferase (COMT) (Eisenberg et al. 1999 ) and monoamine oxidase A (MAO-A) (Manor et al. 2002) . Furthermore, Brookes et al. (2006) reported association with noradrenaline transporter SLC6A2 (NET1) and the noradrenaline receptors ADRA1A, ADRB2 and MAO-A in a study of 51 candidate genes of the International Multisite ADHD Gene project (IMAGE) sample. Nevertheless, subsequent studies of the above gene variants have yielded conflicting results (Gizer et al. 2009 ). Here, we sought to confirm a role of NA system genes in the aetiology of ADHD, performed a systematic multi-marker mapping of 14 noradrenergic genes and conducted transmission disequilibrium analysis in Irish Australian ADHD nuclear families.
Materials and methods
A total sample of 810 individuals, comprising 270 ADHD nuclear families (full trios) ascertained in Ireland and Australia, was investigated. The first sample comprised 201 full trios recruited throughout Ireland from child psychiatric clinics and schools in west County Dublin and from the Hyperactive and Attention Deficit Children's Support Group of Ireland. Confirmations of diagnoses were made by trained psychiatrists using the parent form of the child and adolescent psychiatric assessment (Angold et al., 1995) . Additional information regarding symptom severity and pervasiveness was gained using the Conners' Parent ADHD Rating Scale-Revised: Long Version (CPRS-R: L) and the Comprehensive ADHD Teachers Rating Scale. The second sample comprised 69 Australian nuclear families with ADHD recruited from the Royal Children's Hospital, Melbourne, and the Queensland Brain Institute, Brisbane. ADHD diagnosis was determined using the parent version of the Anxiety Disorders Interview Schedule for Children (Silverman and Albano 1996) according to DSM-IV criteria. As for the Irish cohort, parents completed the CPRS-R:L. The Irish sample had a mean age of 10.3 years (SD03.83) compared to the Australian sample which had a mean age of 9.6 years (SD02.6). All individuals were of Caucasian ethnic background.
SNP selection and genotyping
Ninety one SNPs in the following 14 genes were genotyped in 270 ADHD nuclear families with an average SNP density per gene ranging from 0.74 to 9.9 kb/SNP: the noradrenaline transporter (SLC6A2), the noradrenaline receptors ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRAB1, ADRB2 and ADRAB3, the enzymes DBH, COMT, MAO-A and phenylethanolamine n-methyltransferase (PNMT). The following criteria were used for SNP selection.
1. Tagging SNPs that captured other variants within the same gene or closely mapped region with linkage disequilibrium (LD) of r 2 ≥0.8. Minor allele frequencies of the examined SNPs >5 %. 2. SNPs that have previously been reported to be associated with ADHD in published studies. 3. SNPs that are known to be functional or potentially functional in modulating the expression of the examined gene, particularly those that mapped to a promoter region or were within 500 bp of the exon-intron boundaries. 4. Exonic SNPs that alter amino acid sequences which may affect protein structure.
Eighty eight SNPs were commercially genotyped at KBiosciences using the competitive allele-specific PCR system (KASPar) and Taqman™ chemistries for genotyping. In addition, three markers at DBH (rs1611115 and rs6271) and COMT (rs4680) were genotyped in-house using Taqman™ assays and the ABI sequence analyzer 7900HT.
Statistical analysis
The standard transmission disequilibrium test (TDT) which avoids potential population stratification bias was implemented to test for association of single-SNP and multi-marker haplotypes. For each gene, corrections for multiple testing were conducted by performing 10,000 permutations of the observed p values for all SNPs. Haplotype blocks in each of the examined genes were determined according to the block definition described by Gabriel et al. (2002) . Association with single SNPs, haplotypes and measurements of LD (expressed as D′ and r 2 ) were calculated using the program Haploview, which can be accessed at http:www.broad.mit.edu/mpg/haploview/. To minimise spurious results (type I and II errors) resulting from correction for multiple testing, we decided to restrict haplotype analysis to genes in which at least one SNP achieved nominal significance at p≤0.05. Further, haplotype association tests were conducted for all blocks in each gene separately, and correction for the multiplicity was performed using 10,000 permutations.
The default setting of Haploview is known to identify the largest haplotype blocks based on the strength of LD among markers and to avoid overlap between haplotype blocks. Haplotype analysis based on the Haploview default setting may therefore result in the loss of information from markers that are not in strong LD with each other. Thus, an additional exploratory analysis using sliding windows of five-, sixand seven-SNP haplotypes in the genes showing nominal association (p≤0.05) with ADHD was also conducted.
Results

Single-SNP and haplotype analyses
The chromosomal location, gene size (kbp), number of examined SNPs and gene coverage are presented in Table 1 . The reference sequence, chromosomal position, genotyping success rate and allele frequencies of each examined SNP are also supplied in Table S1 of the "Electronic supplementary materials". Allele frequencies of the two samples (Irish and Australians) were either identical or very similar, and no significant differences that could potentially produce spurious results (type I or II errors) by combining the two samples were observed. The genotype frequencies of one marker (rs486354 at ADRA1A) significantly deviated from that expected under the Hardy-Weinberg equilibrium and, hence, was eliminated from the analysis.
Both single-SNP and multi-marker haplotype analyses were implemented to examine a possible association between ADHD and 90 SNPs of 14 noradrenergic system genes covering 413 kb. TDT analysis of the examined markers is presented in Table S2 of the "Electronic supplementary materials". Nominal associations between ADHD and four genes, each involving one or more markers (p value ranges from 0.0065 to 0.05), were observed ( Table 2) . Evidence of associations was identified with SNPs in SLC6A2, ADRA1A, ADRA1B and ADRA2B.
Of particular interest were four SLC6A2 SNPs, three of which showed evidence of association with ADHD in previous studies (Yang et al. 2004; Bobb et al. 2005; Xu et al. 2005) . These SNPs were rs3785157 (χ 2 03.7, p 00.054, OR 01.3), rs8047672 (χ 2 07.21, p 00.0072, OR 02.04), rs5569 (χ 2 07.01, p 00.008, OR 01.44) and rs2242447 (χ 2 07.42, p00.0065, OR01.47). We next examined whether the direction of association was consistent across the Irish and Australian cohorts. For each rs8047672, rs5569 and rs2242447, the pattern of association was similar across the two cohorts. Specifically, for rs8047672, the association with G allele was significant in the Australian sample and trending in the Irish sample (Australian: χ 2 06.4, p00.011, OR02.5; Irish: χ 2 02.7, p00.1, OR01.38). For rs5569, both samples showed biased transmission of allele A to cases, but neither sample attained statistical significance in isolation (Irish: χ 2 03.78, p00.052, OR01.38; Australian: χ 2 03.46, p00.062, OR01.6). Allele T of rs2242447 was nominally associated with ADHD in the Irish sample (χ 2 05.23, p0 0.022, OR 01.46) and trending in the Australian sample (χ 2 02.2, p00.14, OR01.5).
Nominal association of ADHD with rs10503800 at ADRA1A (χ 2 05.26, p 00.022, OR 01.37), the SNPs rs6888306 and rs7737796 at ADRA1B (χ 2 05.95, p 0 0.0147, OR01.46; χ 2 04.23, p00.039, OR01.32, respectively) and the SNP rs2312955 at the ADRA2B (χ 2 05.02, p00.025, OR01.37) was also observed. However, except for the SNP rs2312955, none of these associations remained significant (Table 2 ) after adjusting the p values using 10,000 permutations. A highly significant association between ADHD and a five-SNP SLC6A2 haplotype comprising the markers rs36009, rs1800887, rs8049681, rs2242447 and rs9930182 (χ 2 09.39, p00.002, OR01.51) was observed, which survived permutation testing (p00.019). Further, haplotype analysis using a sliding window revealed another ADHDassociated haplotype in SLC6A2 comprising the SNPs rs3785157, rs5568, rs8047672, rs5569 and rs36009 (χ 2 0 7.89, p-corrected00.036, OR01.37; Table 3 ). Evidence for association was also observed with ADRA1B haplotypes made of six markers: rs2030373, rs6884105, rs756275, rs6892282, rs6888306 and rs13162302 (χ 2 07.79, pcorrected00.042, OR02.74; Table 3 ).
Discussion
Pharmacological, animal model, neurophysiological and genetic association studies have suggested a role of the noradrenergic pathway in ADHD. In line with this proposal, nominally significant associations were observed between ADHD and one or more SNPs in four noradrenergic genes (SLC6A2, ADRA1A, ADRA1B and ADRA2B). Furthermore, haplotype analysis demonstrated significant SLC6A2 (pcorrected00.019) and ADRA1B (p-corrected00.042) associations with ADHD, suggesting that the haplotype effect may be driven by functional risk variants within or adjacent to the ADHD-associated regions.
SLC6A2
The SLC6A2 protein (NET1) is known to control the level of NA in synapses. Abnormalities in NA level potentially increase the risk of developing ADHD. Several previous studies showed no relation between SLC6A2 gene variants and ADHD, including those reported by Barr et al. (2002) , McEvoy et al. (2002) and De Luca et al. (2004) . In contrast, a study by Yang et al. (2004) identified a significant association with the variant G1287A (rs5569) and response to methylphenidate for hyperactive-impulsive subscale. Further, significant ADHD associations with rs3785157 and rs998424 were reported in a sample from Maryland, USA (Bobb et al. 2005 ). The association with rs3785157 was confirmed by Xu et al. (2005) , who also reported a trend toward association with rs998424 and rs2242447. Notably, the markers rs5569, rs3785157 and rs2242447 showed increased transmission to ADHD cases in this study but were not significant after permutation adjustment. Furthermore, the SNP rs8047672 also showed evidence of association with ADHD in our study and has been reported to associate with the response to atomoxetine treatment in children with ADHD (Ramoz et al. 2009 ). Interestingly, rs8047672 is mapped 136 bp from rs12708954 (which has the strongest pharmacogenetic association with responder status), and the two are in very strong LD (D′01, r 2 00.93). The SNPs (rs8047672, rs5569
and rs2242447) which exhibited biased transmission to ADHD cases in this study are in strong LD with one or more of the eight SNPs reported to associate with atomoxetine response (Ramoz et al. 2009 ). It is important to emphasise that SNPs showing evidence of association with ADHD in our study and all the above mentioned studies are located between intron 7 (rs3785157) and 3′UTR (rs9930182) of SLC6A2, spanning a region of 11.46 kbp. The LD relations of all examined markers are presented in Fig. 1 . Our haplotype analysis shows a significant association between ADHD and a haplotype made of the SNPs rs36009, rs1800887, rs8049681, rs2242447 and rs9930182 (Table 3) . This haplotype spans a region of 8 kbp and maps between intron 10 and the 3′UTR of the gene. The second SLC6A2 ADHD-associated haplotype (rs3785157, rs5568, rs8047672, rs5569 and rs36009) is also mapped within the above 11.46 kbp region, further demonstrating the importance of this region for genetic risk for ADHD. Association with SLC6A2 gene variants also receives support from two major studies. The first is the IMAGE consortium, which reported association with rs3785143 and rs11568324 (Brookes et al. 2006) . The second is a quantitative genome-wide association (Lasky-Su et al. 2008, personal communication) which observed evidence of association between rs17307096 and ADHD inattentive symptoms. Notably, markers rs17307096 and rs3785143 are mapped 823 bp apart in intron 1 and are in a relatively strong LD (D′01, r 2 00.17). These findings either suggest the presence of a second SLC6A2-ADHD association region mapping to intron 1, which is separated from the region of association around the 3′UTR by~34 kbp, or alternatively reflect weak LD among the SNPs of the two regions. Careful inspection of LD relations in our data (see Fig. 1 ) and those of HapMap shows that the two regions of association map into separate haplotype blocks. We note, however, that since there is a weak LD between these two haplotype blocks, one cannot assert definitively which region is driving the observed association with ADHD.
The evidence of association between the above SLC6A2 regions and ADHD suggests the potential existence of a functional risk variant(s) for ADHD. The relatively small sample size of this and other studies may explain the failure to attain statistical significance (after correction for multiple testing) and indicates that the effect size of associated variants is likely to be small. Further examination of the associated regions with bigger sample sizes is required to validate these findings.
ADRA1B
Hyperactivity induced by d-amphetamine, cocaine or morphine in mice lacking the alpha1b adrenergic receptor is dramatically decreased compared with wild-type littermates. Moreover, behavioural sensitizations induced by these psychostimulants are significantly decreased in knock-out mice compared to wild-type mice (Drouin et al. 2002) , suggesting that ADRA1B is a reasonable candidate gene for ADHD. TDT analysis revealed increased frequencies of alleles at rs6888306 (χ 2 05.95, p00.014, OR01.46) and rs7737796 (χ 2 04.23, p0 0.03, OR01.23) in the ADHD cases. A previous report (Brookes et al. 2006) showed a weak association between rs952037 and ADHD. However, none of the above SNPs show LD with that observed by Brookes et al. (2006) . Nevertheless, gene-based tests of association in a recent ADHD-genome-wide association study (GWAS) (Mick et al. 2010) reported that ADRA1B is one of 19 classical ADHD candidate genes that had one or more SNP showing biased transmission to cases at p≤0.05. Specifically, the SNPs rs13436303, rs31682 and rs752438 (mapping to the 5′ flanking region) and rs2030373 (intron 1) of ADRA1B showed biased transmission to ADHD cases. Interestingly, an increased transmission of the C allele of rs2030373 was also observed in this study, although it was not statistically significant (χ 2 03, p0 0.085 OR01.28). Moreover, the SNP rs7737796 (χ 2 04.23, p00.3, OR01.23) is in strong LD (D′00.88, r 2 00.39) with rs2030373, indicating that the results of this study provide further evidence of a role of ADRA1B in ADHD. Although no significant haplotype association was observed using haplotypes defined by the Haploview default settings, a six-SNP haplotype comprising rs2030373, rs6884105, rs756275, rs6892282, rs6888306 and rs13162302 was observed to associate with ADHD (χ 2 07.80, p-corrected00.042, OR02.74) by using sliding window analysis (Table 3) . Notably, this haplotype is rare (2.6 %), extends for 19 kbp and comprises marker rs2030373, which was reported to show evidence of association in the GWAS by Mick et al. (2010) . Although this finding supports a role of ADRA1B in ADHD, further studies are essential.
ADRA2B
Alpha-2-adrenergic receptors (ADRA2A, ADRA2B and ADRA2C) play a critical role in regulating neurotransmitter release from sympathetic nerves and from adrenergic neurons in the central nervous system. ADRA2A and ADRA2C have been implicated in ADHD in previous studies (Comings et al. 1999) . However, ADRA2B has not been extensively examined for association with ADHD. The ADHD-associated ADRA2B SNP (rs2312955) is mapped in the 5′ flanking region and is the only marker that has been examined in this gene. Examination of more markers, preferably at the coding and control regions of the gene, is required to investigate the role (if any) of ADRA2B in ADHD.
In conclusion, the results of this and several other studies show that genes of the noradrenergic pathway contribute to the genetic risk for ADHD. The failure of some studies to detect significant associations after correction for multiple comparisons suggests the need for larger collaborative samples that can rigorously test the hypothesis that noradrenergic system gene variants confer risk for ADHD.
